By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian biotech DiaGenic said it will use its gene expression technology to identify biomarkers of early-stage Alzheimer's disease for Pfizer, under a deal announced today by DiaGenic.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.